KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ardelyx (ARDX) EPS (Weighted Average and Diluted) (2013 - 2026)

Ardelyx posted quarterly EPS (Weighted Average and Diluted) of -$0.15 for Q1 2026, up 11.76% year-on-year from -$0.13 in Q1 2025, and down 1400.0% on a QoQ basis from -$0.01 in Q4 2025.

Ardelyx (ARDX) has 12 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.15 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 11.76% year-over-year to -$0.15; the trailing twelve-month figure through Mar 2026 stood at -$0.24 (down 9.09% YoY), and the FY2025 full-year result was -$0.26, down 52.94% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.15, down from -$0.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.11 in Q4 2022 and bottomed at -$0.21 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.1 (2023), against an average of -$0.08.
  • The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) jumped 135.48%; it then plunged 218.18% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.11 in 2022, then slumped by 218.18% to -$0.13 in 2023, then jumped by 115.38% to $0.02 in 2024, then sank by 150.0% to -$0.01 in 2025, then slumped by 1400.0% to -$0.15 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.15 (Q1 2026), -$0.01 (Q4 2025), and -$0.08 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -4.43
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 4.02
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.51
10 Ardelyx 1.48 Bn 1.25 Bn 89.66 Mn -0.15

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.15
Dec 31, 2025 -0.01
Jun 30, 2025 -0.08
Mar 31, 2025 -0.17
Dec 31, 2024 0.02
Sep 30, 2024 0.00
Jun 30, 2024 -0.07
Mar 31, 2024 -0.11
Dec 31, 2023 -0.13
Sep 30, 2023 0.03
Jun 30, 2023 -0.08
Mar 31, 2023 -0.13
Dec 31, 2022 0.11
Sep 30, 2022 -0.14
Jun 30, 2022 -0.19
Mar 31, 2022 -0.21
Dec 31, 2021 -0.31
Sep 30, 2021 -0.42
Jun 30, 2021 -0.45
Mar 31, 2021 -0.34
Dec 31, 2020 -0.32
Sep 30, 2020 -0.20
Jun 30, 2020 -0.28
Mar 31, 2020 -0.25
Dec 31, 2019 -0.31
Jun 30, 2016 -0.83
Sep 30, 2015 -0.70
Jun 30, 2015 0.42
Mar 31, 2015 -0.19
Jun 30, 2014 0.18
Mar 31, 2014 -2.44
Sep 30, 2013 -0.81
Jun 30, 2013 -0.81